Lenzilumab

Drug Profile

Lenzilumab

Alternative Names: KB-003

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Developer Humanigen; KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic myelomonocytic leukaemia
  • Research Solid tumours
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
  • 27 Jul 2017 KaloBios intends to apply for Orphan Drug status and Rare paediatric designation for Myeloid leukaemia (juvenile myelomonocytic leukaemia)
  • 29 Nov 2016 KaloBios plans a phase I trial in Juvenile myelomonocytic leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top